Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23TM in Adults Aged 50 Years and Older
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2018
Price : $35 *
At a glance
- Drugs GSK 1437173A (Primary) ; Pneumococcal vaccine
- Indications Pneumococcal infections; Varicella zoster virus infections
- Focus Pharmacodynamics; Registrational
- Acronyms ZOSTER-035
- Sponsors GlaxoSmithKline
- 28 Jul 2016 Status changed from active, no longer recruiting to completed.
- 11 Jul 2016 This trial was completed in Estonia (end date: 17-06-2016), according to European Clinical Trials Database.
- 18 Jan 2015 Planned End Date changed from 1 Nov 2015 to 1 Jul 2016 as reported by ClinivalTrials.gov.